http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-H08308571-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5128cfc84a0fb189fceb3cd240c44493 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-02 |
| filingDate | 1995-05-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0c53ffceb47aa5346844d92c69d6628d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7f83c3f8e29e2cf60dc9fbc5f6ce806c |
| publicationDate | 1996-11-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-H08308571-A |
| titleOfInvention | Fused cell stabilizer |
| abstract | (57) [Summary] [Structure] Stabilizer for human type monoclonal antibody-producing fused cells containing ouabain and cell division inhibitor as active ingredients, stable method for producing human type monoclonal antibody, and enhanced production of the human type monoclonal antibody Law. [Effect] To provide a stabilizing agent that enables stable or enhanced production of human type monoclonal antibodies by fused cells, which has been considered to be almost impossible, for a long period of at least half a year to about 1 year or more, and Using a common myeloma such as mouse myeloma, rat myeloma, or mouse-human heteromyeloma as a fusion partner, it was possible to produce a humanized monoclonal antibody by a cell fusion method with established methodologies. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-101869574-A |
| priorityDate | 1995-05-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 120.